Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor α therapies: Does the risk change with the time since start of treatment?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor α therapies: Does the risk change with the time since start of treatment?

Published:2009-10-29 Issue:11 Volume:60 Page:3180-3189
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis & Rheumatism

Author:

Askling Johan,van Vollenhoven Ronald F.,Granath Fredrik,Raaschou Pauline,Fored C. Michael,Baecklund Eva,Dackhammar Christina,Feltelius Nils,Cöster Lars,Geborek Pierre,Jacobsson Lennart T.,Lindblad Staffan,Rantapää-Dahlqvist Solbritt,Saxne Tore,Klareskog Lars

Funder

Swedish Cancer Society

Stockholm County Council

ARTIS

Swedish Biologics Register

Wyeth-Ayerst

Schering-Plough

Abbott Immunology

Roche

Bristol-Myers Squibb

The South Swedish Anti-TNF Register has received funding from the King Gustav V

Österlund

Kock Foundations

Reumatikerförbundet

Swedish National Board of Health and Welfare

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/art.24941/fullpdf

Reference21 articles.

1. TNF-α in promotion and progression of cancer;Balkwill;Cancer Metastasis Rev,2006

2. TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility;Van Horssen;Oncologist,2006

3. NF-κB: tumor promoter or suppressor?;Perkins;Trends Cell Biol,2004

4. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration;Brown;Arthritis Rheum,2002

5. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials;Bongartz;JAMA,2006

Cited by 209 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician;Nature Reviews Rheumatology;2024-01-12

2. A Multidisciplinary Approach to Patients with Psoriasis and a History of Malignancies or On-Treatment for Solid Tumors: A Narrative Literature Review;International Journal of Molecular Sciences;2023-12-16

3. Risk of Cutaneous T Cell Lymphoma with Psoriasis Biologic Therapies;Dermatology and Therapy;2023-12-03

4. Systemic Inflammatory Disorders, Immunosuppressive Treatment and Increase Risk of Head and Neck Cancers—A Narrative Review of Potential Physiopathological and Biological Mechanisms;Cells;2023-09-01

5. Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors;Drug Safety;2023-07-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3